Nrx Pharmaceuticals, Inc., A Clinical-Stage Biopharmaceutical Company, Announced That Its First Clinical Trial Site Has Been Contracted (With Others Expected In Near Future) And That First Dosing Of Patients Is Expected In Early 2023.This Phase 3 Clinical Trial Of Nrx-101 Is For The Treatment Of Severe Bipolar Depression With Acute Suicidal Ideation And Behaviour (Sbd-Asib), A Lethal Condition That Currently Takes The Lives Of Thousands Of Americans Each Year. Nrx-101 Is The First Investigational Medicine To Target This Condition, For Which The Only Currently Approved Treatment Is Electroconvulsive Therapy.Based On Preliminary Efficacy Demonstrated In The Company
